Paysign Reports 51% Q1 Revenue Growth, 110% Net Income Increase, Exceeds Guidance

summarizeSummary

Paysign, Inc. announced strong first-quarter 2026 financial results, with revenue up 51% and net income more than doubling, exceeding previous guidance and reinforcing confidence in full-year targets.

check_boxKey Events

• Exceptional Q1 Financial Performance

  Revenue grew 50.8% to $28.04 million, and net income increased 110.3% to $5.44 million ($0.09 diluted EPS), significantly exceeding prior guidance.

• Strong Growth Across Segments

  Pharma revenue surged 81.9% driven by 45 new patient affordability programs, while plasma revenue increased 24.9% with 89 new centers.

• Significant Margin Expansion

  Operating margin improved to 23.8% from 13.4% year-over-year, and Adjusted EBITDA more than doubled to $10.59 million.

• Positive Full-Year Outlook

  Management reiterated full-year 2026 guidance, expecting net income to nearly double over 2025 and expressing confidence in achieving the upper half of their ranges.

auto_awesomeAnalysis

Paysign's first-quarter results demonstrate robust operational execution and strong market demand for its patient affordability and plasma donor compensation solutions. The substantial revenue and profit growth, coupled with significant margin expansion, indicates effective cost management and scalability. Exceeding Q1 guidance and reiterating an optimistic full-year outlook, with expectations for net income to nearly double, suggests sustained positive momentum and strengthens the company's financial position for future investments.